<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070782</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 681257-CS6</org_study_id>
    <nct_id>NCT03070782</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to
      evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of
      different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in
      patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in plasma Lp(a) from baseline at the primary analysis time point for ISIS 681257 treatment groups compared to placebo.</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis will be the comparison of percent change from baseline to primary analysis time point in fasting Lp(a) between ISIS 681257 treatment groups and pooled placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of different doses and dosing regimens of ISIS 681257 as measured by proportion of patients with treatment-related adverse events by severity, and number of patients meeting safety stopping rules</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The safety and tolerability of ISIS 681257 will be assessed by determining the incidence, severity, and dose relationship of adverse effects and changes in the laboratory parameters by dose. Safety results in subjects dosed with ISIS 681257 will be compared with those from subjects dosed with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of ISIS 681257 on the percent change from baseline in LDL-C.</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in fasting LDL-C will be compared between each ISIS 681257 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of ISIS 681257 on the proportion of patients who achieve plasma Lp(a) ≤ 50 mg/dL.</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who achieve ≤ 50 mg/dL in fasting Lp(a) at the primary analysis time point will be compared between each ISIS 681257 treatment group and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of apolipoprotein B (apoB).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in fasting apoB will be compared between ISIS 681257 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of oxidized phospholipids (OxPL) on apolipoprotein (a) [apo(a)] [OXPL-apo(a)].</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in fasting OxPL apo(a) will be compared between ISIS 681257 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of oxidized phospholipids (OxPL) on apoB (OXPL-apoB).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in fasting OxPL-apoB will be compared between ISIS 681257 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate plasma Cmax of ISIS 681257 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Cmax will be calculated for the treatment groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate plasma Tmax of ISIS 681257 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Tmax will be calculated for the treatment groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate plasma AUC values of ISIS 681257 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>AUC values will be calculated for the treatment groups.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Elevated Lipoprotein(a)</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ISIS 681257 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 681257 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 681257 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 681257 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 681257 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Sterile Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline (0.9% NaCl) by volume to match dose and regimen of active comparator depending on Cohort assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 681257</intervention_name>
    <description>Randomly assigned to one of the dosing cohorts.</description>
    <arm_group_label>ISIS 681257 Dose 1</arm_group_label>
    <arm_group_label>ISIS 681257 Dose 2</arm_group_label>
    <arm_group_label>ISIS 681257 Dose 3</arm_group_label>
    <arm_group_label>ISIS 681257 Dose 4</arm_group_label>
    <arm_group_label>ISIS 681257 Dose 5</arm_group_label>
    <other_name>AKCEA-APO(a)-LRx, IONIS-APO(a)-LRx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.</description>
    <arm_group_label>Placebo: Sterile Normal Saline</arm_group_label>
    <other_name>Sterile Normal Saline (0.9% NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
             peripheral artery disease

          -  Lp(a) plasma level ≥ 60 mg/dL

          -  Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
             risk factors

        Key Exclusion Criteria:

          -  Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
             stroke/TIA

          -  Within 3 months of Screening: coronary, carotid, or peripheral arterial
             revascularization, major non-cardiac surgery, or lipoprotein apheresis

          -  Heart failure New York Heart Association (NYHA) class IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akcea Therapeutics</last_name>
    <email>Akcea_681257_CS6@worldwide.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>January 31, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IONIS-APO(a)-LRx</keyword>
  <keyword>AKCEA-APO(a)-LRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
